Document Detail


Entry-into-humans study with a new direct renin inhibitor.
MedLine Citation:
PMID:  22418829     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
PURPOSE: To evaluate the pharmacokinetics, pharmacodynamics, safety, and tolerability of escalating single oral doses of ACT-077825, a novel orally active renin inhibitor, in healthy male subjects. METHODS: In this single-center, double-blind, placebo- and active-controlled (with enalapril) randomized study, 70 subjects received a single dose of ACT-077825 (1-1,000 mg), placebo, or enalapril 20 mg under fasted conditions. The main pharmacokinetic endpoints were area under the plasma ACT-077825 concentration-time curve from time zero to infinity and the terminal half-life (t(1/2)). The pharmacodynamic endpoints included immunoactive active renin (iAR) plasma concentrations and plasma renin activity (PRA). Standard laboratory and safety data were collected. RESULTS: Of the few adverse events reported, diarrhea and headache were the most frequent. The pharmacokinetics of ACT-077825 were dose-proportional in the dose range 100 to 1,000 mg. Terminal t(1/2), best characterized following a dose of 1,000 mg, was 41.6 h and t(max) 4-5 h post-dose. ACT-077825 dose-dependently increased iAR and decreased PRA, effects that were associated with a decrease in blood pressure at 1,000 mg, similar to following treatment with enalapril. CONCLUSION: The results provide evidence that ACT-077825, with a pharmacokinetic profile consistent with a once-a-day dosing regimen, may represent an effective antihypertensive agent and pave the way toward a multiple-ascending dose study.
Authors:
Laurent B Nicolas; Marcelo M Gutierrez; Christoph Binkert; Jasper Dingemanse
Related Documents :
22514589 - Photoletter to the editor: scarring alopecia resulting from pyoderma gangrenosum of the...
8699629 - Antihypertensive effect of chronic kt3-671, a structurally new nonpeptide angiotensin a...
8193609 - Evaluation of cilazapril versus captopril in patients with mild to moderate essential h...
8706769 - Haemodynamic interactions of a new calcium sensitizing drug levosimendan and captopril.
2468049 - Effect of cimetidine on the pharmacokinetics and pharmacodynamics of enalapril in norma...
3007909 - Antihypertensive substance in seeds of areca catechu l.
18261879 - Chromium picolinate does not produce chromosome damage.
8679359 - Combination of ondansetron and dexamethasone in the prophylaxis of postoperative nausea...
3161009 - Effect of ultraviolet radiation on guinea pig epidermal langerhans cell cytomembrane: l...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-3-15
Journal Detail:
Title:  European journal of clinical pharmacology     Volume:  -     ISSN:  1432-1041     ISO Abbreviation:  -     Publication Date:  2012 Mar 
Date Detail:
Created Date:  2012-3-15     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  1256165     Medline TA:  Eur J Clin Pharmacol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Department of Clinical Pharmacology, Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, 4123, Allschwil, Switzerland, laurent.nicolas@actelion.com.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers...
Next Document:  Healthcare providers' experiences with adverse drug reactions and adherence challenges in antiretrov...